Stig Lennart Hansson

Develops and commercializes pharmaceutical products

Functions as a College/University

Uminova Invest specializes in seed capital investing. The firm invests exclusively in high-growth projects and businesses with a clear connection to Umeå University or other academic entities and research institutes in the province of Västerbotten, where Umeå is located. Uminova Invest targets science-based projects with unique selling points and significant market potential, in sectors such as biotechnology, IT and medical technology. The firm acquires minority stakes and typically co-invests with their shareholding institutions. In addition to capital they actively contribute business know-how, management support, marketing expertise and access to their network of contacts. They invest primarily in early-stage companies, and may invest during the growth phase as well. Although they aim to exit their investments after three years once their portfolio companies have an established market, Uminova Invest may retain their stake over the longer term. Their preferred exit strategy is through resale, either to the founder or to existing shareholders.

Provides tools and services for membrane protein research

Develops novel treatments for hyperoxaluria leading to kidney damage and potential organ failure

Provides medical devices for cardiac valve surgery

LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions.

Provides cancer therapies based on gen- and cell-therapy

Develops and manufactures pharmaceutical products

Develops medical solutions for mitral valve repair

Operates as a life sciences investment company

Manufactures pharmaceutical products

Develops software for transportation agencies

Conducts research and development of pharmaceuticals treatment for Netherton syndrome

Manufactures pharmaceutical products

Operates as a research based biotech company

Engages in buying and selling of shares

Operates as a holding company through its subsidiaries develops small molecules for treatment of gastric acid related diseases